https://www.ajmc.com/journals/evidence-based-oncology/2016/july-2016/promising-results-with-combination-immunotherapy-in-solid-tumors-and-leukemia
Promising Results With Combination Immunotherapy in Solid Tumors and Leukemia

Surabhi Dangi-Garimella, PhD

As immunotherapy—particularly the checkpoint inhibitors—continues to show promise in solid as well as liquid tumors, clinicians have been evaluating these agents in combination to improve efficacy and outcomes. During a June 4, 2016, session during the annual meeting of the American Society of Clinical Oncology, in Chicago, the results from some of these trials were shared.

Some of the questions that were addressed during the session included: 
Combining Nivolumab and Ipilimumab in SCLC
Scott Joseph Antonia, MD, PhD, chair, Department of Thoracic Oncology Department and program leader of the Immunology Program, H. Lee Moffitt Cancer Center, discussed results of the CheckMate 032 trial, in which the programmed death-1 (PD-1) receptor inhibitor nivolumab was used alone or combined with ipilimumab in the treatment of recurrent small cell lung cancer (SCLC).1 
 
It has been over a year since nivolumab was approved in the United States for patients who have progressed on their existing treatment for metastatic non-small cell lung cancer (NSCLC)—however, nivolumab was rejected in the United Kingdom by the National Institute for Health and Care Excellence, or NICE, for patients with advanced NSCLC.2 Antonia said that there’s been trivial progress with SCLC, which he described as being a very stubborn disease. While majority of patients respond to frontline chemotherapy, a majority of them relapse, and then the response rates for the next line of treatment plummets, he explained. 
 
Antonia said that CheckMate 032 was designed to evaluate nivolumab, with or without ipilimumab, in advanced tumors including SCLC. Eligibility criteria for trial participation was advanced SCLC with progressive disease after 1 or more platinum-based chemotherapy, regardless of platinum sensitivity or tumor PD-L1 expression. The primary endpoint of the trial was objective response rate (ORR), with secondary endpoints of safety, overall survival (OS), progression-free survival (PFS), and biomarker expression. The 216 patients enrolled in the trial were divided into 3 cohorts: 
Based on the data presented, a majority of the patients in each cohort expressed less than 1% PD-L1. Additionally, 59% of patients in the nivolumab-alone cohort, 48% in the N1/I3 cohort, and 58% in the N3/I1 cohort had received 2 or more prior lines of treatment.
 
Antonia showed toxicity data for the trial, saying that toxicity was greater in the combination arms. “Three treatment-related deaths were observed among the 114 patients treated with the combination therapy. However, patients were willing to remain on their treatment despite the toxicity,” he said. Response rates doubled with the combination therapy, including in platinum-resistant patients. Majority of the responders had a rapid, durable response, and response was independent of PD-L1 expression. Antonia said that PD-L1 negative patients responded just as well. Median OS, he showed, was 7.7 months for the N1/I3 cohort and 6 months for the N3/I1 cohort—significantly greater than the 4 months observed in patients treated with nivolumab alone.

Further, the 1-year OS rate was:
Antonia concluded that the survival rates from this early study are encouraging. The safety profile observed in the CheckMate 032 trial for SCLC was no different from that observed in other diseases treated with the combination, with higher rates of adverse events (AEs) compared with nivolumab alone. Dose expansion trials and studies in combination with other agents are ongoing, Antonia said, and include:
Based on the results of this study, nivolumab 1 mg/kg and ipilimumab 3 mg/kg was the dose of choice for a phase 3 study with this combination in SCLC patients. 
 
Combining PD-L1 Inhibitors With OX40 Agonists
Jeffrey R. Infante, MD, director of the drug development program at Sarah Cannon Research Institute, presented a phase lb dose escalation study of an OX40 receptor agonist, in combination with a PD-L1 inhibitor, in patients with advanced solid tumors.
 
OX40 agonists, Infante said, have a dual mechanism of action: they inhibit regulatory T cells and costimulate effector T cells. This can definitely be complemented by the PD-L1 inhibition. Being a phase 1 study, the primary objective of their trial was to evaluate the safety and tolerability of combining the PD-L1 inhibitor atezolizumab with the OX40 inhibitor MOXR0916. MOXR0916 is a humanized effector-competent agonist IgG1 monoclonal antibody. The secondary objectives of the study included:
A total of 51 patients were enrolled in the study, with a median age of 58 years. The most common tumor types were NSCLC, renal cell carcinoma (RCC), ovarian cancer, gastroesophageal (GE) junction cancer, and soft-tissue sarcoma. A log that detailed whether patients had received prior treatment with an anti–PD-1 or anti–PD-L1 agent was maintained. A 3+3 dose-escalation was conducted with a 21-day window to evaluate dose-limiting toxicity (DLT), Infante explained. Escalating doses of MOXR0916, in combination with a fixed 1200-mg dose of atezolizumab, were administered every 3 weeks. An expansion cohort to enable immune profiling of serial tumor biopsies was also enrolled in the trial. Prior immunotherapy with adequate washout was allowed if there was no history of grade 3 or greater immune-mediated AEs. 
 
Infante said that the combination was well tolerated overall, with no DLT, deaths, or grade 4 or higher toxicity. A grade 3 pneumonitis in 1 patient was controlled with antibiotics and steroids. “No truly dose-dependent AE was observed,” he concluded.
 
The current expansion regimen is MOXR0918 at 300 mg in combination with atezolizumab 1200 mg, every 3 weeks. Significantly, the study did observe PD-L1 modulation in patients who had had immediate prior therapy with single-agent anti-OX40 or anti–PD-1. 
 
Efficacy studies, Infante said, are ongoing for the combination in melanoma, RCC, NSCLC, urothelial carcinoma, and triple-negative breast cancer.

Discussant’s Comments
Following the 2 presentations, Jedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center, discussed the findings. Expressing his excitement with the results that were presented, Wolchok said that questions remain. “We need additional numbers on patients along with further information on the nature of the response,” he said, including whether the combination treatment generates a deeper response. Information on the PD-L1 status in each group is also important to understand, Wolchok said. “We also need studies that evaluate other agents for combination studies.”
 
With respect to the OX40 study, Wolchok said that lab-based studies have shown a 100% survival response in mice treated with an OX40 agonist with azetolizumab. He was quite impressed by the biomarker analysis done by the study group, evaluating the upregulation of PD-L1. “OX-40 is a potentially promising agent,” Wolchok concluded. EBO
 

Print | AJMC Printing...